HK Stock Market Move | CONCORD HC GP (02453) rose nearly 6% in the afternoon, and its Huzhou Tahe Cancer Hospital Proton Therapy Center in Guangzhou was officially put into operation.

CONCORD HC GP (02453) rose nearly 6% in the afternoon, reaching a 5.71% increase at the time of publication, at HKD 14.44 with a turnover of HKD 1456.06 million. On the news front, CONCORD HC GP announced earlier that the China National Medical Products Administration had approved the registration application for the proton therapy equipment medical device registration certificate of the company's equipment supplier on December 6, 2024. CONCORD HC GP's official account on December 12 stated that the proton therapy center at Guangzhou Taihe Cancer Hospital, under the company, will start operations on December 16, 2024, to officially treat cancer patients. According to Frost & Sullivan data, the Chinese proton therapy market is expected to grow from 310 million RMB in 2022 to 5.3 billion RMB in 2026, with the potential to reach 17.49 billion RMB in 2030. It is reported that Guangzhou Taihe Cancer Hospital, as the first medical institution in South China equipped with proton therapy system, not only covers the Guangdong-Hong Kong-Macao Greater Bay Area and southern provinces, but also has the potential to expand to the whole nation and even countries in East Asia and Southeast Asia.